93 related articles for article (PubMed ID: 12957331)
1. CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype.
Nordin C; Dahl ML; Eklundh T; Eriksson M; Sjöberg S
Eur Neuropsychopharmacol; 2003 Oct; 13(5):333-5. PubMed ID: 12957331
[TBL] [Abstract][Full Text] [Related]
2. Taurine in plasma and CSF: a study in healthy male volunteers.
Samuelsson M; Dahl ML; Gupta RC; Nordin C
Amino Acids; 2009 Mar; 36(3):529-33. PubMed ID: 18663559
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
4. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
6. Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.
Hellman K; Roos E; Osterlund A; Wahlberg A; Gustafsson LL; Bertilsson L; Fredrikson S
Br J Clin Pharmacol; 2003 Sep; 56(3):337-40. PubMed ID: 12919185
[TBL] [Abstract][Full Text] [Related]
7. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 phenotypes among Malays in Malaysia.
Ismail R; Hussein A; Teh LK; Nizam Isa M
J Clin Pharm Ther; 2000 Oct; 25(5):379-83. PubMed ID: 11123490
[TBL] [Abstract][Full Text] [Related]
9. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin.
Mulder AB; van Lijf HJ; Bon MA; van den Bergh FA; Touw DJ; Neef C; Vermes I
Clin Pharmacol Ther; 2001 Dec; 70(6):546-51. PubMed ID: 11753271
[TBL] [Abstract][Full Text] [Related]
10. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
11. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
[TBL] [Abstract][Full Text] [Related]
12. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
Llerena A; Dorado P; Ramírez R; Calzadilla LR; Peñas-Lledó E; Álvarez M; Naranjo ME; González I; Pérez B;
Pharmacogenomics; 2013 Dec; 14(16):1973-7. PubMed ID: 24279852
[TBL] [Abstract][Full Text] [Related]
14. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
Nordin C; Dahl ML; Eriksson M; Sjöberg S
Lancet; 1997 Jul; 350(9070):29-30. PubMed ID: 9217719
[No Abstract] [Full Text] [Related]
15. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
Solai LK; Pollock BG; Mulsant BH; Frye RF; Miller MD; Sweet RA; Kirshner M; Sorisio D; Begley A; Reynolds CF
J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
[TBL] [Abstract][Full Text] [Related]
16. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
17. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
20. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
LLerena A; Berecz R; de la Rubia A; Dorado P
J Psychopharmacol; 2002 Dec; 16(4):361-4. PubMed ID: 12503836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
